Recent health news highlights include a CDC team assessing bird flu in Washington state farm workers, CVS's leadership change ...

Depending on when you last got vaccinated, that COVID-19 shot may no longer be a good match for the variants expected to ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

However, Novavax's shares recently dropped by about 20% in one day after it announced a clinical setback. The biotech's stock ...

An analysis by Li Tao, MD, MS, PhD, director of real-world evidence at Gilead Sciences, and colleagues looked at statistical ...

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. (“Novavax” or ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Novavax announced Wednesday that the Food and Drug Administration (FDA) has placed a clinical hold on its application for a ...

Analyst Eric Joseph of J.P. Morgan maintained a Sell rating on Novavax (NVAX – Research Report), retaining the price target of $9.00.

The FDA approved the company's COVID vaccine in October 2023. The stock has gained 111% in the year to date, while the S&P 500 SPX has gained 22%. This content was created by MarketWatch, which is ...

Novavax’s decision has left managers of the Biologics Manufacturing Centre, which was built with nearly $130-million in federal funds, working to drum up other business for the 55,000-square-foot ...

Novavax's protein-based shot is an option for COVID vaccination this season, joining refreshed formulas from Moderna and Pfizer. Jessica is a writer on the Wellness team with a focus on health ...